Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104) - Heinemann, Volker; Vehling-Kaiser, Ursula; Waldschmidt, Dirk; Kettner, Erika; Märten, Angela; Winkelmann, Cornelia; Klein, Stefan; Kojouharoff, Georgi; Gauler, Thomas C; von Weikersthal, Ludwig Fischer; Clemens, Michael R; Geissler, Michael; et al. (Gut, 2013)
Keywords: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; cancer; Capecitabine; Chemotherapy; Clinical trials; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Erlotinib; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil - administration & dosage; Fluorouracil - analogs & derivatives; Gemcitabine; Germany; Humans; KRAS; Male; Medical prognosis; Metastasis; Middle Aged; Mutation; Neoplasm Staging; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Prospective Studies; Quinazolines - administration & dosage; Regulatory approval; Studies; Survival Analysis; Treatment Outcome; Germany